טוען...
Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition
Genetic disruption or pharmacologic inhibition of glucagon signaling effectively lowers blood glucose but results in compensatory glucagon hypersecretion involving expansion of pancreatic α-cell mass. Ben-Zvi et al. recently reported that angiopoietin-like protein 4 (Angptl4) links glucagon receptor...
שמור ב:
| הוצא לאור ב: | Proc Natl Acad Sci U S A |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
National Academy of Sciences
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5347591/ https://ncbi.nlm.nih.gov/pubmed/28143927 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1620989114 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|